Investigate The Mechanism Of Jinqi Jiangtang Tablet In Treatment Of Type 2 Diabetes Mellitus Based On Network Pharmacology

The incidence of type 2 diabetes mellitus is increasing in the world and it has become the third largest non-communicable disease threatening human life and health following the cardiovascular and tumors.How to treat type 2 diabetes mellitus reasonably is an important clinical problem that needs to be overcome.Jinqi Jiangtang Tablet is a safe and effective traditional Chinese medicine for the treatment of type 2 diabetes mellitus,however its mechanism is unclear so far.The BICOMS-2,Netdraw,Ucinet6.0,gCLUTO and other software were employed to analyze the research key characteristics of traditional Chinese medicine in the treatment of type 2 diabetes mellitus of Chinese and English research publications.Exploring the molecular mechanism of Jinqi Jiangtang Tablet in treatment of type 2 diabetes mellitus applies network pharmacology method and molecular docking technology.The Cytoscape 3.7.2 software was imposed to build the "Chinese medicine-Compounds-Targets" action network;Then,Microsoft Excel 2016 software and Graph Pad Prism 8.0.2 software were performed to draw function enrichment diagrams and pathway heat maps;R software was utilized to draw the bubble diagram of the pathway;Finally,Schr?dinger software was used to do molecular docking.The Cancer Genome Atlas Program(TCGA)was applied to analyze the gene expression of non-diabetic and diabetic pancreatic cancer patients and the Least Absolute Shrinkage and Selection Operator(LASSO)Cox regression was used to predict its prognosis.In addition,the results were verified by mutual exchange of genetic biomarkers in Gene Expression Omnibus(GEO)and the International Cancer Genome Consortium(ICGC).Studying the genetic biomarkers related to the prognosis of non-diabetic and diabetic pancreatic cancer patients aims to provide reference for clinicians and related researchers.The main results and conclusions were as follows:(1)The current status and hotspots of research on traditional Chinese medicine in treatment of type 2 diabetes mellitus: In recent years,research on traditional Chinese medicine in treatment of type 2 diabetes mellitus has been increasing continuously.We collected and filtered 4,045 Chinese studies and 654 English studies.The result of publications showed 82.5%of Chinese literature not published in CDSC journals and the quality of the current research was not high and the Impact Factors of English publications were relatively low.The cooperation between different regions and authors was less and in the future,the cooperation should be strengthened.The research hotspots focused on the methods,mechanism of action,clinical effects and research progress of traditional Chinese medicine in treatment of type 2 diabetes mellitus.(2)The Network Pharmacology of Jinqi Jiangtang Tablet in the treatment of type 2 diabetes mellitus showed that quercetin,kaempferol,luteolin,β-sitosterol,isorhamnetin and other 41 compounds regulated JUN,TP53,TNF,AKT1,MAPK1 and other 166 key targets involved in2605 biological functions and 124 important pathways to play a therapeutic role.The molecular docking results show that the binding energy of quercetin,kaempferol,luteolin and JUN,TP53,TNF,AKT1,and MAPK1 were all ≤-7.0 kcal/mol,mainly affected pathways in cancer,PI3K-Akt signaling pathway,AGE-rage signaling pathway in diabetic complications,Hepatitis B and Fluid shear stress and atherosclerosis,which confirmed the molecular mechanism of Jinqi Jiangtang Tablet in the treatment of type 2 diabetes mellitus.(3)The Least Absolute Shrinkage and Selection Operator(LASSO)Cox regression was used to predict its prognosis.An integrated gene prognostic biomarker consisted of fourteen low-risk genes(TTTY9B,RNF121,FHAD1,GTF2F2,ADAMTS19,LHFPL1,DHDH,LOC256880,SLC25A41,ZNF233,C6orf195,PCDHA11,LOC401127,TUBBP5)and six high-risk genes(CRCT1,MUC20,RTP1,C10orf111,SPACA5,FZD10)in pancreatic cancer with non-diabetes.Meanwhile,and another integrated gene prognostic biomarker consisted of five low-risk genes(SYS1-DBNDD2,NCRNA00167,IRX5,ZNF77,CATSPERG)and three high-risk genes(ZNF793,GBP6,FOSL1)in pancreatic cancer with diabetes.Therefore,the prognostic value of gene biomarker in pancreatic cancer with non-diabetes and diabetes were all greater than clinical traits(HR=1.102,P-value < 0.0001;HR=1.212,P-value < 0.0001).Gene biomarkers in pancreatic cancer with non-diabetes was validated in two independent datasets(GEO、ICGC).This study aimed to provide reference for clinical practitioners and related researchers.